WSTAM
OSIR

Wilbanks Smith & Thomas Asset Management’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,500
Closed -$61K – 1602
2018
Q3 		$61K Buy
+5,500
New +$55K ﹤0.01% 641

Other funds holding OSIR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's OSIR Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q4 2018, closing a stake of 5,500 shares — an estimated $61K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in OSIR in Q3 2018 and held it in 1 quarter. The position peaked at $61K in Q3 2018. 46 funds tracked by Wall St. Rank hold OSIR as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 5,500 Osiris Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $61K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Osiris Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Osiris Therapeutics, Inc. Common Stock position peaked at $61K in Q3 2018.
  • 46 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.